Mitoxantrone: A review of its use in multiple sclerosis

CNS Drugs

Volumn 18, Issue 6, 2004, Pages 379-396

  Scott, Lesley J ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Mitoxantrone; Multiple sclerosis; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; IMMUNOMODULATING AGENT; MEPREDNISONE; MITOXANTRONE; PLACEBO;

ACUTE GRANULOCYTIC LEUKEMIA; AMENORRHEA; ANEMIA; B LYMPHOCYTE; BACKACHE; BLOOD CELL COUNT; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRANULOCYTOPENIA; HEADACHE; HELPER CELL; HOSPITAL ADMISSION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIFESPAN; MENSTRUATION DISORDER; MONOTHERAPY; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; STOMATITIS; TREATMENT CONTRAINDICATION; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DATABASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HUMANS; MEDLINE; MITOXANTRONE; MULTIPLE SCLEROSIS;

EID: 2442496353     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418060-00010     Document Type: Review

References (80)

1. Maurer M, Rieckmann P. Relapsing-remitting multiple sclerosis: what is the potential for combination therapy? Biodrugs 2000; 13 (3): 149-58
2. Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis: better outcomes for patients and society? Drugs 2003; 63 (15): 1525-33
3. Corboy JR, Goodin DS, Frohman EM. Disease-modifying therapies for multiple sclerosis. Curr Treat Options Neurol 2003 Jan; 5 (1): 35-54
4. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359 (9313): 1221-31
5. Rice GPA. Treatment of secondary progressive multiple sclerosis: current recommendations and future prospects. Biodrugs 1999; 12 (4): 267-77
6. Rudick RA, Cohen JA, Weinstock-Guttman B, et al. Management of multiple sclerosis. N Engl J Med 1997; 337 (22): 1604-11
7. Brod SA, Lindsey W, Wolinsky JS. Multiple sclerosis: clinical presentation, diagnosis and treatment [published erratum appears in Am Fam Physician 1997; 55 (2): 448]. Am Fam Physician 1996; 54 (4): 1301-11
8. Poser CM, Paty DW, Schienberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13 (3): 227-31
9. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46 (4): 907-11
10. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994; 36 Suppl.: S6-11
11. Weinstock-Guttman B, Jacobs LD. What is new in the treatment of multiple sclerosis? Drugs 2000; 59 (3): 401-10
12. Khan O, Zabad R, Caon C, et al. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis. CNS Drugs 2002; 16 (8): 563-78
13. Kilpatrick TJ, Soilu-Haenninen M. New treatments in multiple sclerosis. Aust N Z J Med 1999; 29 (6): 801-10
14. Schluep M, Bogousslavsky J. Emerging treatments in multiple sclerosis. Eur Neurol 1997; 38 (3): 216-21
15. Waubant EL, Goodkin DE. Assessing efficacy in clinical trials of treatments for multiple sclerosis: issues and controversy. CNS Drugs 1996; 6 (6): 462-73
16. Comi G. Why treat early multiple sclerosis patients? Curr Opin Neurol 2000; 13 (3): 235-40
17. Faulds D, Balfour JA, Chrisp P, et al. Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 41 (3): 400-49
18. Dunn CJ, Goa KL. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Drugs Aging 1996; 9 (2): 122-47
19. Ehninger G, Schuler U, Proksch B, et al. Pharmacokinetics and metabolism of mitoxantrone: a review. Clin Pharmacokinet 1990; 18 (5): 365-80
20. Wiseman LR, Spencer CM. Mitoxantrone: a review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 1997; 10 (6): 473-85
21. Khoury SJ, Bharanidharan P, Bourcier K, et al. Immunologic effects of mitoxantrone in patients with multiple sclerosis [abstract no. S33.002]. Neurology 2002; 58 Suppl. 3: A245-6
22. Fidler JM, DeJoy SQ, Gibbons Jr JJ. Selective immunomodulation by the antineoplastic agent mitoxantrone 1. Suppression of B lymphocyte function. J Immunol 1986; 137 (2): 727-32
23. Fidler JM, DeJoy SQ, Smith III FR, et al. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986; 136 (8): 2747-54
24. Wang BS, Lumanglas AL, Silva J, et al. Inhibition of the induction of alloreactivity with mitoxantrone. Int J Immunopharmacol 1986; 8 (8): 967-73
25. Levine S, Gherson J. Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues. Int J Immunopharmacol 1986; 8 (8): 999-1007
26. Watson CM, Davison AN, Baker D, et al. Suppression of demyelination by mitoxantrone. Int J Immunopharmacol 1991; 13 (7): 923-30
27. Sloboda AE, Oronsky AL, Kerwar SS. Studies of the effects of mitoxantrone on adjuvant induced arthritis in rats. Clin Immunol Immunopathol 1986; 40 (2): 236-43
28. Baker D, O'Neill JK, Davison AN, et al. Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent - elucidation by the action of mitoxantrone. Clin Exp Immunol 1992; 90 (1): 124-8
29. Lublin FD, Lavasa M, Viti C, et al. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987; 45 (1): 122-8
30. Ridge SC, Sloboda AE, McReynolds RA, et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 1985; 35 (1): 35-42
31. Levine S, Saltzman A. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol 1986; 13 (2): 175-81
32. Mustafa M, Diener P, Sun J-B, et al. Immunopharmacologic modulation of experimental allergic encephalomyelitis: low dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity. Scand J Immunol 1993; 38 (6): 499-507
33. Lublin FD, Maurer PH, Berry RG, et al. Delayed, relapsing experimental allergic encephalomyelitis in mice. J Immunol 1981; 126 (3): 819-22
34. Lublin FD. Relapsing experimental allergic encephalomyelitis: an autoimmune model of multiple sclerosis. Springer Semin Immunopathol 1985; 8 (3): 197-208
35. Serono. Novantrone®: mitoxantrone for injection concentrate (US) [online]. Available from URL: http://www.novantrone.com/pdf/ novantrone_prescribing_info.pdf [Accessed 2004 Feb 27]
36. Schleyer E, Kamischke A, Kaufmann CC, et al. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. Leukemia 1994; 8 (3): 435-40
37. Ehninger G, Proksch B, Heinzel G, et al. The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs 1985; 3 (2): 109-16
38. Smyth JF, Macpherson JS, Warrington PS, et al. The clinical pharmacology of mitoxantrone. Cancer Chemother Pharmacol 1986; 17 (2): 149-52
39. Alberts DS, Peng Y-M, Leigh S, et al. Disposition of mitoxantrone in cancer patients. Cancer Res 1985; 45 (4): 1879-84
40. Lu K, Savaraj N, Loo TL. Pharmacological disposition of 1,4-dihydoxy-5-8-bis[[2[(2- hydroxyethal)amino]ethyl] amino]-9,10- anthracenedione dihydrochloride in the dog. Cancer Chemother Pharmacol 1984; 13 (1): 63-6
41. Stewart DJ, Green RM, Mikhael NZ, et al. Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 1986; 70 (11): 1255-61
42. Savaraj N, Lu K, Manuel V, et al. Pharmacology of mitoxantrone in cancer patients. Cancer Chemother Pharmacol 1982; 8 (1): 113-7
43. Chiccarelli FS, Morrison JA, Cosulich DB, et al. Identification of human urinary mitoxantrone metabolites. Cancer Res 1986; 46 (9): 4858-61
44. Hartung H-P, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360 (9350): 2018-25
45. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria [see comments]. J Neurol Neurosurg Psychiatry 1997; 62 (2): 112-8
46. Bastianello S, Pozzilli C, Dandrea F, et al. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 1994; 21 (3): 266-70
47. De Castro S, Cartoni D, Millefiorini E, et al. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol 1995; 35 (6): 627-32
48. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244 (3): 153-9
49. Mauch E, Kornhuber HH, Krapf H, et al. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992; 242 (2-3): 96-102
50. Nosewoithy JH, Hopkins MB, Vandervoort MK, et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993; 43 (7): 1401-6
51. Krapf H, Mauch E, Fetzer U, et al. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 1995; 37 (2): 113-9
52. Malone M, Lomaestro B. Outcomes assessment of drug treatment in multiple sclerosis clinical trials. Pharmacoeconomics 1996; 9 (3): 198-210
53. Polman CH, Hartung H-P. The treatment of multiple sclerosis: current and future. Curr Opin Neurol 1995; 8 (3): 200-9
54. Filippi M, Horsfield MA, Ader HJ, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998; 43 (4): 499-506
55. Arnold DL, Matthews PM. MRI in the diagnosis and management of multiple sclerosis. Neurology 2002; 58 Suppl. 4 (8 Suppl. 4): S23-31
56. Wanke LA, Durgin TL, Goodkin D, et al. Estimated resource use and cost of mitoxantrone in patients with progressive-relapsing and secondary-progressive multiple sclerosis: results from MIMS trial [abstract no. P02.029]. Neurology 2001; 56 Suppl. 3: A100
57. Brassat D, Recher C, Waubant E, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002 Sep 24; 59 (6): 954-5
58. Heesen C, Bruegmann M, Gbdamosi I, et al. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone [letter]. Mult Scler 2003 Mar; 9 (2): 213-4
59. Cattaneo C, Almici C, Borlenghi E, et al. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia 2003 May; 17 (5): 985-6
60. Crossley RJ. Clinical safety and tolerance of mitoxantrone. Semin Oncol 1984; 11 (3 Suppl. 1): 54-8
61. Edan G, Brassat D, Clanet M, et al. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients [abstract no. S23.005]. Neurology 2002; 58 Suppl. 3: A168
62. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002 Sep 24; 59: 909-13
63. Avasarala JR, Cross AH, Clifford DB, et al. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 2003 Feb; 9 (1): 59-62
64. Mikol DD, Bernitsas E. Safety and tolerability of mitoxantrone plus dexrazoxane therapy in multiple sclerosis patients [abstract no. P06.084]. Neurology 2002; 58 Suppl. 3: A459-60
65. van Oosten BW, Truyen L, Barkhof F, et al. Choosing drug therapy for multiple sclerosis: an update. Drugs 1998; 56 (4): 555-69
66. Rudick R. Contemporary immunomodulatory therapy for multiple sclerosis. J Neuro-Opthalmol 2001; 21 (4): 284-91
67. Frohman E, Phillips T, Kokel PA-C, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002; 8 (4): 227-36
68. Fox RJ, Cohen JA. Multiple sclerosis: the importance of early recognition and treatment. Cleveland Clin J Med 2001; 68 (2): 157-71
69. Becker CC, Gidal BE, Fleming JO. Immunotherapy in multiple sclerosis, part 2. Am J Health Syst Pharm 1995; 52 (19): 2105-20
70. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [published erratum appears in Neurology 2002; 59 (3): 480]. Neurology 2002; 58 (2): 169-78
71. Larner AJ, Farmer SF. Recent advances: neurology. BMJ 1999; 319 (7206): 362-6
72. Calabresi P. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology 2002; 58 (8 Suppl. 4): S10-22
73. Lea AP, Goa KL. Copolymer-1: a review of its pharmacological properties and therapeutic potential in multiple sclerosis. Clin Immunother 1996; 6 (4): 319-31
74. Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs 2002; 16 (12): 825-50
75. Wagstaff AJ, Goa KL. Recombinant interferon-β-1a: a review of its therapeutic efficacy in relapsing-remitting multiple sclerosis. Biodrugs 1998; 10 (6): 471-94
76. Holliday SM, Benfield P. Interferon-β-1a: a review of its pharmacological and therapeutic potential in multiple sclerosis. Biodrugs 1997; 8 (4): 317-30
77. Ziemssen T, Neuhaus O, Kohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf 2001; 24 (13): 979-90
78. Weilbach FX, Gold R. Disease modifying treatments for multiple sclerosis: what is on the horizon? CNS Drugs 1999; 11 (2): 133-57
79. Goodin DS, Arnason BG, Coyle PK, et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61 (10): 1332-8
80. Bashir K, Whitaker JN. Current immunotherapy for demyelinating disease. Arch Neurol 2002; 59 (5): 726-31